Navigation Links
Clot-Busting Therapy Under Review
Date:9/28/2009

for people with the most severe form of heart attack.

The study of 3,602 people who underwent angioplasty found a 28 percent lower incidence of death and major coronary problems in those who received the higher dose.

While similar results have been reported in trials comparing 600-milligram to 300-milligram doses of Plavix in other groups of patients having angioplasty, this report is the first done in people with the most severe form of heart attack.

But "Plavix is a problematic drug," said Simon, who wrote an editorial accompanying the journal report, in part because some people are genetically resistant to its activity. And so, he said, "interventional cardiologists are confused right now about what is the most effective regimen."

Prasugrel has been shown to be superior to clopidogrel in one or more trials, and a study presented at the San Francisco meeting gave the advantage to ticagrelor in a head-to-head trial with clopidogrel.

"The biggest news was that ticagrelor reduced total mortality by an absolute 1 percent, which was a relative 19 percent reduction in mortality compared to clopidogrel," said Dr. Christopher Cannon, an attending cardiologist at Brigham and Women's Hospital in Boston, who presented the trial results at the meeting.

In addition, less bleeding was seen in people who had bypass surgery and were given ticagrelor rather than clopidogrel, he said.

One great advantage of ticagrelor is that its effects wear off in about 48 hours, compared to five days for clopidogrel, which reduces the possibility of unwanted bleeding, Cannon said.

Still, most people treated at Brigham and Women's Hospital get clopidogrel, with prasugrel reserved for cases in which excess bleeding is especially dangerous, he said.

The transition to the newer clot-dissolving drugs is complicated by the issue of cost, Simon said. A generic version of Plavix is now available in Europe and is expected to be avai
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Clot-Busting Drug Offers New Approach to DVT
2. Researchers fine-tune clot-busting treatment for bleeding in brain
3. Clot-Busting Treatment Improves Bleeding Stroke Outcomes
4. Few Stroke Patients Get Clot-Busting Drug
5. Vision restoration therapy shown to improve brain activity in brain injured patients
6. HIV therapy in pregnancy-data support WHO recommendations
7. Family-based treatment more effective than supportive psychotherapy in treating bulimia
8. Trial to Test Gene Therapy for Angina in Women
9. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
10. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
11. Chemotherapy may be culprit for fatigue in breast cancer survivors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clot-Busting Therapy Under Review
(Date:5/20/2013)... May 20, 2013 Widely regarded as ... genital plastic surgery and women’s sexual health, Dr. Goodman ... Board of http://www.labiaplastysurgeon.com , the nationally ranked ... proud to be a member of this informative and ... the appointment. “I’ve already worked with the President ...
(Date:5/20/2013)... May 20, 2013 AURORA, Colo. – ... online accredited university, has developed a Bachelor of ... assess how they feel about continuing their education and ... print out the complimentary worksheet, respond to ten statements ... they rate on a BSN-readiness scale. , New industry ...
(Date:5/20/2013)... Columbus, OH (PRWEB) May 20, 2013 ... an experienced medical device law firm, report that two ... the coming months in state and federal litigations established ... On June 11th, the first C.R. Bard bellwether trial ... Court, Southern District of West Virginia. (In re: ...
(Date:5/20/2013)... Durham, N.C. (PRWEB) May 20, 2013 ... Training Institute (IFPTI), will speak at North Carolina Food ... Food is Good Business: The Need for Partnerships – ... , The two-day conference, scheduled for May 22-23 at ... role partnerships across the food sector have in protecting ...
(Date:5/19/2013)... Houston,TX (PRWEB) May 20, 2013 Due ... companies with online advertising, MileageAds.com has decided to invite ... advertisements through their ad network. , Businesses in ... of success with online marketing, specifically with ad networks. ... advice, information and legal services and are unsure where ...
Breaking Medicine News(10 mins):Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 2Health News:Globally Respected Feminine Cosmetic Genital Surgeon Joins Board of Industry Leading Labiaplasty Medical Website 3Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 2Health News:American Sentinel University Develops New Worksheet to Help Nurses Determine BSN-Readiness 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 2Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 3Health News:Transvaginal Mesh Lawyers at Wright & Schulte LLC Look Ahead to Upcoming Vaginal Mesh Lawsuit Bellwether Trials 4Health News:IFPTI Executive Director to Speak at North Carolina Food Safety and Defense Task Force Annual Conference 2Health News:Mileageads Ad Network Now Invites Bloggers and Business Owners in Mesothelioma Sector to Advertise on Their Ad Network 2
... solutions to tackle obesity, the latest on the Northwick ... sport and the Olympics will be highlighted at ... Pharmacological Society (BPS), Europe,s leading pharmacological research society, is ... attracting experts from across the world. , Running from ...
... Public Relations Worldwide (Ogilvy PR), an integrated global communications ... five-year comprehensive communications support contract with the National Cancer ... will be performed by Ogilvy PR,s Washington, DC-based Social ... consulting subsidiary, Feinstein Kean Healthcare (FKH). , ...
... But American physicians often overlook the illness, delaying diagnosis ... doctors view leprosy as a scourge of Biblical times ... U.S. cases, with more diagnosed each year, experts say. ... remains a largely forgotten illness, U.S. physicians are often ...
... peginterferon in combination with ribavirin for previously untreated children ... , KENILWORTH, N.J., Dec. ... today announced that the U.S. Food and Drug Administration ... and REBETOL(R) (ribavirin, USP) combination therapy for use in ...
... ANN ARBOR, Mich., Dec. 12 Terumo Corporation ... that,they have entered into an agreement to settle ... companies have a number of lawsuits pending,in which ... The litigations all,involve methods and devices used ...
... Dec. 12 Dignitas Personae (The Dignity of ... Doctrine of the Faith (CDF) on ethical issues arising from ... and human procreation in our heavily scientific age, said Cardinal ... of Catholic Bishops. , , ...
Cached Medicine News:Health News:Leading pharmacologists to meet in Brighton 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Leprosy Lingers in the U.S. 2Health News:Leprosy Lingers in the U.S. 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 2Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 3Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 4
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
The Urology C-Arm Table features motorized actuation of height, X-Y, lateral roll and Trendelenburg motions of the tabletop, and is fully accessorized for urologic procedures....
... UroVantage from HealthTronics is ... most versatile urology table ... leap forward in design ... urologists by urologists, the ...
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... The Maxxis™ 400 is a bariatric ... safety for individuals in the home care ... 1000 lbs. (or combined weight of 2) ... depending on frame size selected , ...
Medicine Products: